Terms: = Liver cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Clinical Outcome
657 results:
1. COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma.
Liu J; Han D; Xuan J; Xie J; Wang W; Zhou Q; Chen K
Aging (Albany NY); 2024 Mar; 16(6):5264-5287. PubMed ID: 38466642
[TBL] [Abstract] [Full Text] [Related]
2. Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.
Yang Q; Zhuo Z; Qiu X; Luo R; Guo K; Wu H; Jiang R; Li J; Lian Q; Chen P; Sha W; Chen H
J Transl Med; 2024 Jan; 22(1):122. PubMed ID: 38297333
[TBL] [Abstract] [Full Text] [Related]
3. Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.
Xie LL; Huang YB; Dong KR; Yang SB; Shen C; Ma YY
BMC Pediatr; 2024 Jan; 24(1):8. PubMed ID: 38172842
[TBL] [Abstract] [Full Text] [Related]
4. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of clinical outcome between laparoscopic and open hepatectomy of high difficulty score for hepatocellular carcinoma: a propensity score analysis.
Ng KKC; Cheng KC; Kung JWC; Ho KM; Lok HT; Fung AKY; Chong CCN; Cheung SYS; Lee KF; Wong J; Lai PBS
Surg Endosc; 2024 Feb; 38(2):857-871. PubMed ID: 38082015
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial.
Vogl TJ; Martin SS; Gruber-Rouh T; Booz C; Koch V; Nour-Eldin NA; Hussainy Said MN
Rofo; 2024 May; 196(5):482-490. PubMed ID: 38065541
[TBL] [Abstract] [Full Text] [Related]
7. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.
Li J; Delamarre A; Wong VW; de Lédinghen V
United European Gastroenterol J; 2024 Mar; 12(2):219-225. PubMed ID: 37987101
[TBL] [Abstract] [Full Text] [Related]
8. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
[TBL] [Abstract] [Full Text] [Related]
9. 10 years, 100 robotic major hepatectomies: a single-center experience.
McCarron F; Cochran A; Ricker A; Mantha R; Driedger M; Beckman M; Vrochides D; Martinie J
Surg Endosc; 2024 Feb; 38(2):902-907. PubMed ID: 37845533
[TBL] [Abstract] [Full Text] [Related]
10. Optimal Follow-up of Incidental Pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
12. Transarterial chemoembolization
Yang B; Yuan M; Yang T; Liao Z; Wu H
Oncol Res; 2022; 30(1):23-33. PubMed ID: 37304009
[TBL] [Abstract] [Full Text] [Related]
13. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: "Standing on the Shoulders of Giants".
Zwart MJW; van den Broek B; de Graaf N; Suurmeijer JA; Augustinus S; Te Riele WW; van Santvoort HC; Hagendoorn J; Borel Rinkes IHM; van Dam JL; Takagi K; Tran KTC; Schreinemakers J; van der Schelling G; Wijsman JH; de Wilde RF; Festen S; Daams F; Luyer MD; de Hingh IHJT; Mieog JSD; Bonsing BA; Lips DJ; Abu Hilal M; Busch OR; Saint-Marc O; Zeh HJ; Zureikat AH; Hogg ME; Koerkamp BG; Molenaar IQ; Besselink MG;
Ann Surg; 2023 Dec; 278(6):e1232-e1241. PubMed ID: 37288547
[TBL] [Abstract] [Full Text] [Related]
14. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract] [Full Text] [Related]
15. Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry.
Brink P; Kalisvaart GM; Schrage YM; Mohammadi M; Ijzerman NS; Bleckman RF; Wal T; de Geus-Oei LF; Hartgrink HH; Grunhagen DJ; Verhoef C; Sleijfer S; Oosten AW; Been LB; van Ginkel RJ; Reyners AKL; Bonenkamp HJ; Desar IME; Gelderblom H; van Houdt WJ; Steeghs N; Fiocco M; van der Hage JA
Eur J Surg Oncol; 2023 Sep; 49(9):106942. PubMed ID: 37246093
[TBL] [Abstract] [Full Text] [Related]
16. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract] [Full Text] [Related]
17. clinical significance of plasma PD-L1
Xu P; Liu J; Chen H; Shang L; Wang F; Zhu Y; Guo Y; Li F; Yan F; Xie X; Li L; Gu W; Lin Y
Ann Hematol; 2023 Sep; 102(9):2435-2444. PubMed ID: 37162517
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of the S100 calcium-binding protein family members in hepatocellular carcinoma.
Wei R; Feng OQ; Hui YZ; Huang X; Ping LS
Biosci Rep; 2023 Jul; 43(7):. PubMed ID: 37133437
[TBL] [Abstract] [Full Text] [Related]
19. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC.
Li S; Xia H; Wang Z; Zhang X; Song T; Li J; Xu L; Zhang N; Fan S; Li Q; Zhang Q; Ye Y; Lv J; Yue X; Lv H; Yu J; Lu W
Hepatology; 2023 Oct; 78(4):1079-1091. PubMed ID: 37114494
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract] [Full Text] [Related]
[Next]
